AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 19 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - For years, scientists have been driven to develop a vaccine for hepatitis C virus (HCV) but have failed. New information about viral N-linked glycosylation may soon change that.
"We investigated the role played by N-glycans in the immunogenicity of HCV E1 envelope glycoprotein, a naturally poor immunogen," research collaborators in Europe said in the December 2001 issue of Journal of Virology.
Generating plasmid-based constructs containing E1 protein mutants for which the N-linked glycosylation site had been changed, INSERM investigator A. Fournillier, in conjunction with others at Bio-Merieux, Innogenetics, the University of Belgium, and the Pasteur Institute tested the mutant particles for stability and efficiency as well as secretion activity in vitro and after injection into research mice.
"Whereas some mutations had no or only minor effects on the antibody titers induced, mutation of the fourth glycosylation site (N4) significantly enhanced the anti-E1 humoral response in terms of both seroconversion rates and antibody titers," Fournillier and team reported.
Additionally, the N4 mutant caused the production of higher HCV-like antibody titers than those created by vectors containing wild-type antigen, investigators noted (Induction of ...
Source: HighBeam Research, N-Linked Glycosylation Limits Immune Response To Hepatitis C.(Brief...